ArticleCNS neuroscience & therapeutics2025
Endothelial-Targeted Metallothionein-2 shRNA Nanoparticles Alleviate Migraine-Like Symptoms.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endothelial-Targeted Metallothionein-2 shRNA Nanoparticles Alleviate Migraine-Like Symptoms.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimMigraine is a common chronic neurological disorder manifesting as recurrent moderate-to-severe headaches. It continues to present therapeutic challenges due to population heterogeneity in treatment response. This study investigates the unexplored role of metallothionein-2 (Mt2) in migraine pathophysiology.
methodsWe employed the EGR1-GFP reporter system to identify activated cortical cells induced by nitroglycerin (NTG). RNA sequencing of somatosensory activated cortex cells revealed marked Mt2 upregulation particularly in vascular endothelial cells. To elucidate Mt2's function in migraine pathogenesis, endothelial-targeted nanoparticles encapsulating Mt2-shRNA were engineered and administered via tail-vein injection in migraine model mice. Behavioral assays assessed photophobia and hyperalgesia, while two-photon microscopy evaluated cerebral vasodilation. Pathway enrichment analysis identified critical biological pathways linked to Mt2 activity.
resultsSuppression of Mt2 in endothelial cells via shRNA nanoparticles alleviated migraine-related behaviors, including photophobia and hyperalgesia. RNA-seq and pathway analysis highlighted Mt2's involvement in cerebrovascular endothelial cell development, migration, and inflammation pathways. Crucially, two-photon imaging demonstrated that downregulation of Mt2 markedly attenuated NTG-induced cerebral vasodilation.
conclusionThis study establishes Mt2 as a regulator of vascular tone and inflammatory signaling in migraine pathogenesis, proposing novel therapeutic targets. These findings provide insight in understanding the interplay between vascular dysfunction and migraine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.